Welcome! This is the NEW free version of the SciBITES Pharma News Engine from SciBite. By using this site you to accept our Terms & Conditions which the use of cookies to enhance your user experience.


Here is the latest news for your query in chronological order, most recent articles at the top. Use the options on the right to filter and customise this news feed.

  Todays Biosimilar (Tag) Articles ...

Objectives and methodology of BIOBADASER phase iii.
Medline, Reumatologia clinica, 24-Sep-2017
Rituximab biosimilar evaluated by network meta-analysis.
Medline, Haematologica, 24-Sep-2017
Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays.
Medline, Therapeutic advances in gastroenterology [10] 661-671, 23-Sep-2017
FDA issues draft guidance on statistical approaches to evaluating similarity for biosimilars
http://feedproxy.google.com, , 22-Sep-2017
Biosimilar CT-P13 in treating ulcerative colitis in the real world.
Medline, Minerva gastroenterologica e dietologica [63] 305-306, 22-Sep-2017
Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
Medline, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 22-Sep-2017
Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.
Medline, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 22-Sep-2017

  This Weeks Biosimilar (Tag) Articles ...

Samsung Bioepis will initiate Phase III trials of a Lucentis biosimilar
http://feedproxy.google.com, , 21-Sep-2017
Pfizer goes to Court to allow competition for biologics and expand options for patients
http://www.worldpharmanews.com, , 20-Sep-2017
With its Remicade biosimilar stymied by the brand, Pfizer sues Johnson & Johnson for 'anticompetitive' dealmaking
http://www.fiercepharma.com, , 20-Sep-2017
Revising CMS policy on biosimilars could save $11.4 billion over 10 years, says AAM’s Biosimilars Council
http://feedproxy.google.com, , 20-Sep-2017
Biosimilar Cancer Drug Threat Closing in for Roche
http://www.medscape.com, , 20-Sep-2017
Strategies to Develop Therapeutic N- and O-Hyperglycosylated Proteins.
Medline, Methods in molecular biology (Clifton, N.J.) [1674] 163-181, 20-Sep-2017
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
Medline, Inflammatory bowel diseases, 20-Sep-2017
GP2013: A Rituximab Biosimilar.
Medline, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 20-Sep-2017
Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach.
Medline, Bioanalysis, 20-Sep-2017
Sensitive and comprehensive analysis of O-glycosylation in biotherapeutics: a case study of novel erythropoiesis stimulating protein.
Medline, Bioanalysis, 20-Sep-2017
Investigation of O-glycosylation heterogeneity of recombinant coagulation factor IX using LC-MS/MS.
Medline, Bioanalysis, 20-Sep-2017
New Report Indicates Revising CMS Policy on Biosimilars Could Save $11.4 Billion On Medicines Over 10 Years
http://www.prnewswire.com, , 20-Sep-2017
Biosimilars North America 2017
http://feedproxy.google.com, , 19-Sep-2017
Showing Records 0 ... 20  


SciBite
The Language Of Science

SciBite provides text-analytics and data intelligence software for drug discovery, clinical and competitor intelligence and much more for pharma, healthcare and life sciences.

This is a Limited, Free Service only touching the surface of how SciBite's tools transform biomedical text, literature, patents, internal documents and news into a rich intelligence network. If you'd like to know more, contact us to see how our tools can transform your work today!

Topic Activity & Tools

Get Daily Alerts!

Click For Email & RSS Alerts

About/Links

Name: Biosimilar (Tag)
Type: Technology

Filters

Source:


Must Mention A:


In Context:


Insights

Show Most Frequent


Optional, Only Include Source:


Tools

[Not available (Why?)]